Who
Michael L. Meyers
Director
Company insider
Files Form 4 as: Director, Nuvalent; SVP, Chief Medical Officer, Syndax Pharmaceuticals.
In numbers
- Trades disclosed
- 40
- Buys
- 4
- Sells
- 0
- Bought
- $14K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 6 Feb 2017
- Last trade
- 15 Jul 2026
- Last filed
- 15 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 15 Jul 2026 | NuvalentBiotechnology | SEC FORM 4 Code U | $638K5,146 at $124.00 | filing |
| 15 Jul 2026filed 15 Jul 2026 | NuvalentBiotechnology | SEC FORM 4 Code D | —3,444 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,361 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative | SEC FORM 4 Code D | —8,361 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative | SEC FORM 4 Code D | —3,789 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative | SEC FORM 4 Code D | —4,147 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative · Biotechnology | SEC FORM 4 Code D | —3,789 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalentoption or derivative · Biotechnology | SEC FORM 4 Code D | —4,147 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalent | SEC FORM 4 Code U | $638K5,146 at $124.00 | filing |
| 15 Jul 2026filed 15 Jul 2026 | Nuvalent | SEC FORM 4 Code D | —3,444 | filing |
| 16 Jun 2026filed 18 Jun 2026 | NuvalentBiotechnology | SEC FORM 4 Code A | —3,444 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | Nuvalent | SEC FORM 4 Code A | —3,444 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | Nuvalentoption or derivative | SEC FORM 4 Code A | —4,147 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | Nuvalent | SEC FORM 4 Code A | —2,647 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | Nuvalentoption or derivative | SEC FORM 4 Code A | —3,789 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | Nuvalent | SEC FORM 4 Code A | —2,499 at $0.00 | filing |
News
Syndax Pharmaceuticals (SNDX) – Analysts' Recent Ratings ChangesSNDX · dailypolitical.com · 19 Oct 2026Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down – Here's WhySNDX · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Michael L. Meyers; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.